Grace Therapeutics Reports Increased Net Loss of $15.8 Million for Q2 2026

Grace Therapeutics, Inc. reported a significant increase in net loss for the three months ending June 30, 2026, amounting to $15.8 million, or $0.91 per share, compared to a net loss of $3.4 million, or $0.21 per share, for the same period in 2025. This increase in loss was primarily attributed to a $13.5 million impairment charge related to the company's drug candidates GTx-101 and GTx-102, which were deprioritized in favor of the lead candidate GTx-104. Operating expenses totaled $15.9 million, a substantial rise from $3.1 million in the previous year, driven by the impairment charge and a decrease in general and administrative expenses.

In terms of financial position, Grace Therapeutics reported total assets of $50.1 million as of June 30, 2026, down from $66.7 million at the end of the previous fiscal period. The decline in assets was largely due to the impairment of intangible assets, which reduced the carrying value of GTx-102 and GTx-101. The company’s cash and cash equivalents also decreased to $13.8 million from $17.0 million, reflecting ongoing operational expenditures. However, following a private placement in August 2026, the company raised approximately $9.1 million, which is expected to support its operations and address regulatory requirements related to GTx-104.

Operationally, Grace Therapeutics has streamlined its focus on GTx-104, a novel injectable formulation of nimodipine aimed at treating aneurysmal subarachnoid hemorrhage (aSAH). The company has initiated a dual-source manufacturing strategy to mitigate risks associated with its current contract manufacturer, which faced compliance issues cited in a Complete Response Letter (CRL) from the FDA. The CRL did not indicate any clinical safety or efficacy deficiencies but highlighted the need for additional data and compliance improvements. The company plans to resubmit its New Drug Application (NDA) for GTx-104 once these issues are resolved.

As of June 30, 2026, Grace Therapeutics had 16.3 million shares outstanding, an increase from 16.0 million shares at the end of the previous quarter, reflecting the exercise of pre-funded warrants. The company has also reduced its workforce significantly as part of a strategic realignment plan initiated in May 2023, which aimed to enhance shareholder value by focusing on fewer, more promising drug candidates. The company’s management believes that the existing cash and cash equivalents will be sufficient to sustain operations through at least the next 12 months, although additional capital will be necessary to fund ongoing development and operational needs beyond that period.

Looking ahead, Grace Therapeutics remains committed to addressing the items cited in the FDA's CRL for GTx-104 and is optimistic about the potential for its lead candidate to transform the treatment landscape for aSAH patients. The company is also exploring opportunities to maximize the value of its deprioritized candidates through potential licensing or sale arrangements, although no assurances can be made regarding the success of such efforts.